The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill
Journal of Clinical Laboratory Analysis · 2026-04 · 40 (7)
DOI: 10.1002/jcla.70193 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 16.03.2026. Verfasst von Nadine M C Pouw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Serum Amyloid A Protein. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Siemens Healthineers.
Abstract (Originalsprache)
Background
As the disease course of coronavirus disease 2019 (COVID‐19) can change rapidly, clinically relevant prognostic biomarkers could facilitate clinical‐decision making. Prior research has shown that Serum Amyloid A (SAA) might serve as a prognostic biomarker in patients with COVID‐19. The aim of this study was to determine the discriminative ability of SAA, C‐reactive protein (CRP), ferritin, and procalcitonin (PCT) in patients with COVID‐19 to differentiate between those who remain moderately ill from patients who become severely ill within 7 days of hospitalization.
Methods
Blood samples and disease severity assessment were collected at day 1 (day of hospitalization), 3, 5, and 7 in a Dutch cohort of patients who were hospitalized for COVID‐19. Blood was analyzed for concentrations of SAA, CRP, ferritin, and PCT.
Results
133 patients were included in this study. No differences in concentration of SAA, CRP, ferritin, and PCT at time of hospitalization were observed in patients who remained moderately ill compared to patients who progressed to severe COVID‐19 within 7 days of hospitalization. ROC curve analysis revealed that SAA, CRP, ferritin, and PCT failed to discriminate patients who progressed to severe illness from those who remained moderately ill, with areas under the curve (AUC) of 0.461 for SAA, 0.500 for CRP, 0.528 for PCT, and 0.550 for ferritin.
Conclusion
Our study demonstrates that SAA, CRP, ferritin, and PCT levels at the time of hospitalization failed to discriminate between COVID‐19 patients who remain moderately ill and those who progress to severe disease within 7 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Genetics, University Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Science, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
- Department of Intensive Care, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
- Department of Pulmonology, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands.
ORCID-Profile: Tessa Noordermeer
Förderung
- Siemens Healthineers
Zitieren
APA
Pouw, N. M. C., Noordermeer, T., Klerk, B. B., Birnie, E., Wils, E. J., Rauh, S., Braunstahl, G. J., Mol, S., & van der Zwan-van Beek, E. M. (2026). The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill. Journal of Clinical Laboratory Analysis, 40(7). https://doi.org/10.1002/jcla.70193
Vancouver
Pouw NMC, Noordermeer T, Klerk BB, Birnie E, Wils EJ, Rauh S, et al. The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill. Journal of Clinical Laboratory Analysis. 2026;40(7). doi:10.1002/jcla.70193
BibTeX
@article{Pouw2026,
author = {Pouw, Nadine M C and Noordermeer, Tessa and Klerk, Bianca Boxma-de and Birnie, Erwin and Wils, Evert-Jan and Rauh, Simone and Braunstahl, Gert-Jan and Mol, Sander and van der Zwan-van Beek, Ellen M},
title = {The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 ( COVID ‐19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {7},
doi = {10.1002/jcla.70193}
}
EUVIMED